A phase III single-center randomized trial was performed in order to determine whether the addition of mitomycin C (MMC) and/or doxorubicin to 5-fluorouracil (5-FU) as adjuvant chemotherapy could influence survival in patients with curatively resected gastric cancer.
Introduction
The incidence of gastric carcinoma appears to be declining in Western countries, but it still remains one of the major health problems worldwide, and it is the most common cancer and the leading cause of cancer-related deaths in Korea [1, 2] .
The most effective treatment for gastric carcinoma is curative surgical resection of the primary tumor. However, a substantial number of patients eventually die of locoregional recurrences and/or distant metastases after curative resection. In an attempt to improve prognosis, a number of randomized trials investigating the role of adjuvant chemotherapy have been conducted. However, the efficacy of adjuvant chemotherapy is still controversial and varies between Western and Asian trials [3, 4] . Meta-analysis of Western trials did not demonstrate the benefit of adjuvant chemotherapy after curative resection [5] . Conversely, some Asian studies have demonstrated the efficacy of adjuvant chemotherapy after curative resection [6] [7] [8] [9] [10] . Based on these observations, adjuvant chemotherapy has been recommended in Asian countries. Moreover, Grau et al. [11] reported a positive result for adjuvant mitomycin C (MMC) from a randomized trial, and more recently a meta-analysis for Western trials also suggested that adjuvant chemotherapy conferred survival benefit compared with no-treatment controls [12] . Therefore, although adjuvant chemotherapy following surgery is not regarded as standard treatment in gastric cancer, it is important to reinforce efforts to find more effective adjuvant chemotherapy regimens.
Most studies performed before 1990 used less-effective chemotherapeutic agents, such as nitrosourea. In theory, the best regimen for adjuvant chemotherapy would be the one with the highest response in advanced gastric cancer. Since FAM [5-fluorouracil (5-FU), doxorubicin and MMC] was reported to be effective in advanced gastric carcinoma [13] these drugs have been considered as standard active agents for advanced gastric cancer. It is therefore reasonable to test whether these drugs can play a role as adjuvant therapy in resected gastric cancer.
In this study, we used a 5-FU-alone arm as treatment control and performed a randomized trial to determine whether MMC-containing (FM) and doxorubicin-containing (FAM) regimens could impact on survival when compared with 5-FU alone in resected gastric cancer.
Patients and methods

Patient eligibility and randomization
The criteria for eligibility were: (i) histologically proven gastric adenocarcinoma, (ii) stage IB, stage II, stage IIIA or stage IIIB tumors (American Joint Committee on Cancer, 1988), and (iii) curatively resected. Patients were ineligible if they had coexisting malignant disease, distant metastasis, ascites due to any cause, no lymph node in resected specimens (in these cases it was considered that adequate resection had not been performed), white cell count of <4000/µl, platelet count of <100 000/µl, active infection, or another disease for which systemic chemotherapy was contraindicated. Informed consent was obtained from all patients before entering this trial and the study followed the Helsinki Declaration of the World Medical Association.
To ensure equal distribution of prognostic factors among treatment groups, patients were stratified according to disease stage (stage IB, II, IIIA or IIIB) and the operation method (total or proximal gastrectomy versus distal subtotal gastrectomy) and then randomized to receive one of three chemotherapy regimens. Patients were assigned to one of the three arms by a computer-generated randomization.
Surgery
Curative resection was defined as en bloc removal of gastric tumor with macroscopically and microscopically free proximal and distal resection margins together with en bloc resection of the greater and lesser omentum and adherent organs, and extended lymphadenectomy (D-2 dissection) [14, 15] .
Chemotherapy
Chemotherapy was started within 35 days after surgery according to the schedule ( Table 1 ). The maximum doses per day were limited as follows: 5-FU 1000 mg, doxorubicin 50 mg, and MMC 15 mg.
Patient evaluation, which included a complete blood cell count and blood chemistries, was performed on days 28 and 56 of every cycle. Appropriate dose adjustment was made if hematological and/or nonhematological toxicities were found.
Follow-up evaluation
Patients were evaluated every 4 weeks for the first 12 months, every 3 months for the next 12 months, and every 6 months until the end of the fifth year, and yearly thereafter. Follow-up examinations included the patient's general condition, body weight, performance status, physical examination, complete blood cell count, laboratory tests, chest X-ray (every 3 months for the first 2 years, and subsequently at every followup), and upper gastrointestinal tract series and abdominal ultrasonography (alternately, every 3 months for the first 2 years, and subsequently at every follow-up).
Statistical analysis
The primary end points of the study were overall survival (OS) and disease-free survival (DFS). OS and DFS were measured from the date of surgery. OS was defined as the time from surgery to the date of death from any cause and DFS was measured to the date of recurrence of gastric cancer. The sample size was calculated to ensure that the study had a power of 90% to detect a difference of 20% in the 5-year survival rate at the 5% level of significance (two-tailed). One hundred and twenty-eight patients in each arm were needed. It was assumed that the expected 5-year survival rate for the 5-FU-treated group was 45%.
Survival probabilities were estimated by the life-table method and survival comparison was made by use of the generalized Wilcoxon test. The Cox proportional hazards model was used to find significant prognostic factors. Backward regression was used to find the most significant factors, and variables were eliminated by likelihood-ratio statistics based on conditional parameter estimates. Comparison of three groups based on patient characteristics was performed using the ANOVA method for continuous data and the chi-square test for discrete data. The SPSS program for Windows (Release 9.0.0) was used for analysis.
Results
Between January 1990 and March 1993, 416 patients were randomized; 21 patients (5.0%) were excluded from analysis. Nineteen patients were lost to follow-up evaluation during adjuvant chemotherapy, one patient refused to start chemotherapy after randomization, and another patient violated the protocol.
Patients characteristics
Of the 395 patients, 133 made up the 5-FU group, 131 the FM group and 131 the FAM group. Median age of all patients was 53 (range 21-75) and male to female ratio was 295:100. The (Table 2) .
Primary end points
At the time of survival analysis, the median follow-up duration for all patients was 91 months (range 6-115). The 5-year OS rates were 67.2% for the 5-FU group, 67.0% for the FM group and 66.7% for the FAM group and there was no significant difference among treatment groups (P = 0.97) (Figure 1 ). The 5-year DFS rates were 62.1% for 5-FU, 63.3% for FM and 62.5% for FAM and there was no statistically significant difference (P = 0.83) (Figure 2 (Figure 4 ).
Subset analysis
The 5-year OS rates of male and female patients were 64.4 and 78.1%, respectively, which were statistically different (P = 0.026). The 5-year DFS rates of male and female patients were 61.1 and 69.2%, respectively, but these were not statistically different (P = 0.167 
Relapse
One hundred and thirty-six of 395 patients (34.4%) eventually relapsed and 120 patients died of disease relapse. Around 30% of patients had locoregional relapse and the remaining 70% experienced peritoneal or distant metastasis. There was no significant difference in rate and pattern of relapse among treatment groups (Table 3) . During follow-up, 137 of 395 patients died. Seventeen patients died without evidence of relapse. Causes of these deaths included the following: five from bowel obstruction, three from other malignancy (prostate carcinoma, lung carcinoma and acute leukemia), three from cardiovascular diseases, and two from infections which were not related to chemotherapy (sepsis and pulmonary tuberculosis). The causes of the deaths of the remaining four patients could not be evaluated because cause of death information was not available.
Toxicity
Less hematological toxicities were reported in the 5-FU group than in FM and FAM groups (Table 4 ). In particular, leukopenia was more commonly observed in FM and FAM groups (77% and 72%) than in the 5-FU group (62%) (P = 0.027). Likewise, thrombocytopenia was also more common in FM and FAM groups (29% and 14%) than in the 5-FU group (1.5%) (P <0.001). Five patients experienced infectious episodes, two cases of pneumonia (5-FU group) and three cases of pulmonary tuberculosis (two patients in the 5-FU group and one patient in the FAM group). There were no treatmentrelated deaths.
The most common non-hematological side-effect was nausea and vomiting, but there was no statistical difference among the three groups. Stomatitis was more common in the 5-FU groups and grade 3 or higher stomatitis occurred in 6.8% of 5-FU-treated patients (P <0.001).
Discussion
There have been many clinical trials to evaluate the effects of adjuvant chemotherapy in gastric carcinoma. Although several studies have reported minimal survival benefits for adjuvant chemotherapy, most of the studies have shown no benefit of adjuvant chemotherapy. But this does not necessarily mean that adjuvant chemotherapy of gastric cancer is ineffective in general. In 1993, a meta-analysis of the results of 11 randomized clinical trials published since 1980 failed to show survival benefit as compared with surgical controls, and this was especially true for trials conducted in Western countries [5] . However, this analysis was later criticized for excluding important eligible trials and lack of statistical power [16] . According to an update published again in 1994, an odds ratio of 0.82 [95% confidence interval (CI) 0.68-0.98] was obtained in favor of adjuvant chemotherapy [17] . But this update still had shortcomings in that both Western and Asian trials were analyzed at the same time. It is generally accepted that gastric cancer behaves differently between the West and Asia, possibly due to different etiology, biology and treatment. These differences may cause potentially confounding influences in the interpretation of the results. To address this issue, Earle and Maroun [12] performed a meta-analysis of adjuvant chemotherapy of gastric cancer in non-Asian patients. The odds ratio for death in the adjuvant chemotherapy-treated groups was 0.80 (95% CI 0.66-0.97), suggesting the survival benefit with adjuvant chemotherapy in gastric cancer. Interestingly, subgroup analysis showed that there was In Asia, the strategy for adjuvant therapy seems to be different from that of the West [4] . Some studies, mostly from Japan, demonstrated a benefit for adjuvant chemotherapy, mainly MMC-containing regimens [6] [7] [8] [9] [10] , and there was a tendency to think that a surgery-alone group as the control arm may be considered ethically inappropriate. As a result, postoperative chemotherapy is usually recommended and a treatment control is commonly used. Based on the positive results of a recent meta-analysis in the Western [12] and Asian [6] [7] [8] [9] [10] trials, the approach of finding more effective regimens seems to be important for improving prognosis in resected gastric cancer.
In this study, we used 5-FU alone as a control arm instead of no treatment because 5-FU alone was reported to be marginally effective as a single agent and well tolerated in patients with advanced gastric cancer. Since FAM was found to be an active chemotherapy regimen in advanced gastric cancer in the 1970s [13] , doxorubicin and MMC have been considered active drugs for advanced gastric cancer [18] . Clinical trials on the FAM regimen in an adjuvant setting have been tested, but In this study, we did not see significant survival differences between treatment groups. At the time this study was designed, we assumed that the expected 5-year survival rate of patients with gastric carcinoma in the control arm was 45%. The conclusion is based on the assumption of the initial study design. However, the actual 5-year OS rate of this study (67.2%) was higher than expected. The difference between expected and actual survival rates may be due to improved surgical technique or stage migration with early detection of gastric cancer. We calculated the power with the actual number of patients enrolled in this study based on a 5-year OS rate of 60% for the control arm to detect a difference of 10% at the 5% level of significance (two-tailed). The power is about 22%. With an assumption of 60% 5-year survival in the control arm, 376 patients in each arm are needed to detect a difference of 10% at the 5% level of significance with a power of 80% (two-tailed). To reach a conclusion of adequate statistical power, a large multicenter study is recommended.
According to TNM stage, 5-year OS were 91.3% for stage IB, 76.2% for stage II, 66.5% for stage IIIA and 48.7% for stage IIIB. These survival rates are generally higher than the survival rates reported in Western studies, but similar to Japanese results [22] [23] [24] [25] . The difference in survival rates between Japanese and Western studies may be due to the difference in surgical techniques used in Japan and the West [26] , or due to the initiation time of adjuvant chemotherapy, which is earlier in Japanese studies than Western studies. In our study, the standard surgical procedure was gastrectomy with extended lymphadenectomy, similar to Japanese studies. But, the initiation time of adjuvant chemotherapy was similar to the Western studies, mean 29.5 days. So the difference in surgical procedure between Japan and the West may be a more important cause of the difference in the survival rate. But other causes of the difference may be possible, such as the difference in the biological characteristics of the tumor itself.
In conclusion, the addition of MMC and/or doxorubicin to 5-FU for adjuvant chemotherapy did not prolong the survival of patients with resected gastric cancer in our trial. A multicenter clinical trial with a larger number of patients is recommended.
